Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERENITY CM: Clonidine Micropellets for Lumbosacral Radiculopathy
NCT05614648Phase 3Terminated
- Sponsor
- Sollis Therapeutics
- Start
- Jun 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of clonidine in lumbosacral radiculopathy, sponsored by Sollis Therapeutics. Started Jun 2023; status: terminated.
02
Drugs
clonidine
03
Conditions
lumbosacral radiculopathy
Beyond the preview
Go deeper on NCT05614648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05614648.